

Yuu Moriya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1406329/publications.pdf>

Version: 2024-02-01

7
papers

30
citations

2682572

2
h-index

1872680

6
g-index

7
all docs

7
docs citations

7
times ranked

27
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model. <i>Biopharmaceutics and Drug Disposition</i> , 2020, 41, 283-294.	1.9	0
2	The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1004-1012.	3.3	5
3	Characterization of Fasiglifam-Related Liver Toxicity in Dogs. <i>Drug Metabolism and Disposition</i> , 2019, 47, 525-534.	3.3	7
4	Investigation of disposition for TAK-448, a synthetic peptide of kisspeptin analog, in rats and dogs using the radiolabeled TAK-448 suitable for pharmacokinetic study. <i>Xenobiotica</i> , 2019, 49, 833-839.	1.1	1
5	Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 373-380.	1.9	2
6	Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 543-552.	1.9	1
7	Development and validation of sensitive sandwich ELISAs for two investigational nonapeptide metastin receptor agonists, TAK-448 and TAK-683. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 369-377.	2.8	14